Abstract
Although SARS-CoV-2 is primarily a pulmonary-tropic virus, it is nonetheless responsible for multi-organ failure in patients with severe forms of COVID-19, particularly those with hypertension or cardiovascular disease. Infection requires virus binding to the angiotensin I converting enzyme 2 (ACE2) monocarboxypeptidase, a regulator of blood pressure homeostasis through its ability to catalyze the proteolysis of Angiotensin II (AngII) into Ang(1-7). Although assumed, it had not been proven so far whether the SARS-CoV-2 replication in COVID-19 patients could modulate the expression of the ACE2 receptor and/or the AngII plasma levels. We demonstrate here, that in COVID-19 patients the ACE2 mRNA expression is markedly reduced in circulating blood cells. This ACE2 gene dysregulation mainly affects the monocytes which also show a lower expression of membrane ACE2 protein. Moreover, a significant decrease in soluble ACE2 plasma levels is observed in COVID-19 patients, whereas the concentration of sACE2 returns to normal levels in patients recovered from COVID-19. In the plasma of COVID-19 patients, we also found an increase in AngI and AngII. On the other hand, the plasma levels of Ang(1-7) remains almost stable in COVID-19 patients. Despite the Ang(1-7) presence in the plasma of COVID-19 patients it seems insufficient to prevent the effects of massive AngII accumulation. These are the first direct evidence that the SARS-CoV-2 may affect the expression of blood pressure regulators with possible harmful consequences on COVID-19 outcome.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
CPP 20.04.09/N:20.04.01.83219/N 7626
Funding Statement
This work was supported by the French Government under the Investissements d avenir (Investments for the Future) program managed by the Agence Nationale de la Recherche (French ANR: National Agency for Research) (reference: Mediterranee Infection 10-IAHU-03) the Region Provence Alpes Cote d Azur and European funding FEDER PRIMI
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This research protocol (N National:2020-A00864-35) was submitted to ethical review by the French Participants Protection Committee (CPP East III; CPP president: Dr. P. Peton) prior to commencement of the study and received ethical approval CPP 20.04.09/N:20.04.01.83219/N 7626. (Principal investigator, C. Devaux, Research Director at CNRS; Assay promotor : IHU Mediterranee Infection: Prof Didier Raoult, Director). An informed written consent was obtained from each participant to the protocol (both patients and healthy volunteers).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
ll Data used and mentioned in the manuscript are available and can be consulted upon request.
